The European Organisation for Research and Treatment of Cancer (EORTC) announced the publication of the LUMEN-1 trial protocol in The Journal of Nuclear Medicine. This randomised phase II trial, led by Nathalie Albert et al., focuses on the use of [¹⁷⁷Lu]Lu-DOTATATE for treating patients with recurrent meningioma, a group with limited treatment options following surgery and radiotherapy. It marks the first prospective, randomised clinical trial evaluating SSTR2-targeted radionuclide therapy in this context, and features a comprehensive translational research program that utilizes PET imaging, tumour tissue profiling, dosimetry, and machine learning, potentially leading to new treatment strategies in neuro-oncology.
Wed, 13 Aug 2025 18:30:10 GMT | Oncodaily